Results 111 to 120 of about 21,829 (156)

Repeated insertions at positions 261-280 in KPC-2 highlight a ceftazidime-avibactam resistance hotspot. [PDF]

iScience
Li Y, Salman S, Liu R, Wang K, Gong L, Sun T, Xu H.   +6 more
europepmc   +1 more source

Ceftazidime-Avibactam for the Treatment of Carbapenem-Resistant Organisms: A Prospective, Observational, Single-Center Study

Introduction: The World Health Organization has declared carbapenem-resistant organisms a research and development priority. Although ceftazidime–avibactam was approved around a decade ago, there is still a lack of prospective data on the treatment of ...
Frieder Pfäfflin, Anja Theloe, Leif Erik Sander, Stephan Achterberg, Rasmus Leistner, Miriam Songa Stegemann, Florian Kurth   +6 more
core   +1 more source

Clinical and genomic determinants associated with emergent ceftazidime-avibactam plus aztreonam non-susceptibility in ceftazidime-avibactam resistant <i>Escherichia coli</i>. [PDF]

Antimicrob Agents Chemother
Shropshire WC, Borjan J, Fonseca IY, Pham K, Guerrero M, Liboro K, Young A, Chung JK, Wu C-T, Manzanares A, Bhatti MM, Vuong NN, Handley G, Spallone A, Chemaly RF, Khan A, Shelburne S.   +16 more
europepmc   +1 more source

Ceftazidime-Avibactam Effectiveness in Carbapenem-Resistant Enterobacterales Bacteremia: A Retrospective Cohort Study in Korea. [PDF]

J Korean Med Sci
Lee Y, Seong JE, Lee JA, Kim JH, Ahn JY, Jeong SJ, Choi JY, Yeom JS, Ku NS.   +8 more
europepmc   +1 more source

Ceftazidime and ceftazidime/avibactam [PDF]

, 2016
Wright, Hugh, Endimiani, Andrea
core  

Use of Ceftazidime-Avibactam in a Late-Preterm Newborn with Multidrug-Resistant <i>Enterobacter hormaechei</i> Sepsis. [PDF]

Antibiotics (Basel)
Trizzino M, Notarbartolo V, Pipitò L, Serra G, Romanin B, Carta M, Insinga V, Di Pace MR, Fasciana TMA, Cascio A, Giuffrè M.   +10 more
europepmc   +1 more source

Antimicrobial activity of aztreonam/avibactam and molecular characterization of Enterobacterales not susceptible to ceftazidime/avibactam and/or meropenem/vaborbactam from US medical centres (2016-2024). [PDF]

J Antimicrob Chemother
Sader HS, Papp-Wallace KM, Kimbrough JH, Debabov D, Mendes RE, Castanheira M.   +5 more
europepmc   +1 more source

Outcome of Ceftazidime/Avibactam Versus Alternative Antibiotics for Treatment of Carbapenem-Resistant <i>Enterobacterales</i> Bacteremia in Patients With Hematologic Malignancies. [PDF]

J Korean Med Sci
Jang HM, Baek S, Lim SY, Bae S, Park H, Park HS, Choi Y, Lee JH, Lee JH, Kim SH.   +9 more
europepmc   +1 more source

Efficacy and safety of ceftazidime-avibactam versus tigecycline in the treatment of pneumonia caused by carbapenem-resistant <i>Klebsiella pneumoniae</i>. [PDF]

Front Med (Lausanne)
Yang T, Xu M, Cao L, Shi Y, Shi X.
europepmc   +1 more source

The resistance mechanisms and risk factors of carbapenem-resistant Klebsiella pneumoniae to ceftazidime-avibactam. [PDF]

BMC Res Notes
He X, Liu M, Wang X, Waqas M, Li S, Zhang Y, Liu Z, Wang X.   +7 more
europepmc   +1 more source